Table 5.
Survival outcomes: time (mean and median) spent in health states, undiscounted
| Treatment | Time in PF (months) | Time in PD (months) | Time alive (months) | |||
|---|---|---|---|---|---|---|
| Mean | Median | Mean | Median | Mean | Median | |
| Fulvestrant | 29.58 | 16.56 | 30.51 | 31.28 | 60.08 | 47.84 |
| Anastrozole | 19.56 | 11.96 | 29.38 | 27.60 | 48.95 | 39.56 |
| Letrozole | 22.16 | 14.72 | 21.26 | 23.92 | 43.42 | 38.64 |
| Tamoxifen | 13.16 | 9.20 | 31.89 | 27.60 | 45.05 | 36.80 |
Means are estimated using an area-under-the-curve approach (restricted mean survival time) for the given time horizon; median durations represent the time point at which 50% of patients are still progression free (for progression-free survival) or alive (for overall survival)
PD progressed disease, PF progression free